- Fund Type: Unit Trust
- Objective: Global Asset Allocation
- Asset Class: Asset Allocation
- Geographic Focus: Global
Mirae Asset Lump Sum Goal Convertible Sec Feeder Invst Trust 2 - Equity Balanced
+ Add to Watchlist1742783:KS
923.88 KRW 4.52 0.49%As of 04:24:41 ET on 05/21/2013.
Snapshot for Mirae Asset Lump Sum Goal Convertible Sec Feeder Invst Trust 2 - Equity Balanced (1742783)
| Year To Date: | -1.95% | 3-Month: | -0.55% | 3-Year: | - | 52-Week Range: | 856.94 - 964.78 |
|---|---|---|---|---|---|---|---|
| 1-Month: | +2.24% | 1-Year: | +3.85% | 5-Year: | - | Beta vs KOSPI: | 0.71 |
Fund Profile & Information for 1742783
Mirae Asset Lump Sum Goal Convertible Securities Feeder Investment Trust 2 (Equity Balanced) is an open-end fund incorporated in South Korea. The Fund's objective is to achieve capital gains. The Fund invests in the Equity Master Fund and once it reaches the target price, its assets will be converted and invested in the Bond Master Fund.
| Inception Date: | 10-08-2010 | Telephone: | 82-2-3774-1600 |
|---|---|---|---|
| Managers: | - | ||
| Web Site: | fund.miraeasset.com | ||
Fundamentals for 1742783
| NAV | (on 2013-05-21) 923.88 |
|---|---|
| Assets (M) | (on 2013-05-21) 8,075.55 |
| Fund Leveraged | N |
| Minimum Investment | - |
| Minimum Subsequent Investment | - |
Dividends for 1742783
| Dividend Type | Omitted |
|---|---|
| Dividend Frequency | Annual |
| Last Dividend Net | - |
| Dividend Yield (ttm) | - |
Fees & Expenses for 1742783
| Front Load | - |
|---|---|
| Back Load | - |
| Current Mgmt Fee | 0.60 |
| Redemption Fee | - |
| 12b1 Fee | - |
| Expense Ratio | 1.35 |
Top Fund Holdings for 1742783
Filing Date: 12/31/2012| Name | Position | Value | % of Total |
|---|---|---|---|
| Mirae Asset Maestro Equity Inv | 5,559,935 | 5,192,312,342 | 99.744% |
Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
- 1
- 2
- 3
- 4
- 5
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page